Abstract. Breast cancer, one of the common cancers of women, is the leading cause of death among women below the age of 50 years in western countries. Long non-coding RNAs (lncRNAs) have been shown to be involved in diverse biological processes, both physical and pathological. However, to date, only a few lncRNAs have been functionally identified in breast cancer, and the overall pathophysiological contributions of lncRNAs to breast cancer remain largely unknown. In the present study, we identified a novel lncRNA termed lncFOXO1 through microarray screening. lncFOXO1 is significantly decreased in breast cancer tissues and cell lines and downregulation of lncFOXO1 expression associates with poorer overall survival. Functional assays demonstrated its suppressive role in breast cancer in vivo and in vitro. Mechanistically, lncFOXO1 suppressed the growth of breast cancer by increasing FOXO1 transcription. Moreover, we found that lncFOXO1 associated with BRCA-1-associated protein 1 (BAP1) and regulates its binding and the level of mono-ubiquitinated H2A at K119 (ubH2AK119) at FOXO1 promoter.

Introduction

For several decades, the biological functions have been thought to depend on protein-coding genes. However, protein-coding genes accounts for only approximately 2% of the whole human genome (1). The majority is non-coding RNA (ncRNA) contains housekeeping ncRNAs and regulatory ncRNAs. Long non-coding RNAs (lncRNAs) are transcripts longer than 200 bp without any apparent protein-coding potential (2). Recent studies have demonstrated that lncRNAs are involved in diverse biological processes, both physical and pathological, and that they function as gene regulators at the transcriptional, post-transcriptional and post-translational level by directly interacting with DNA, RNA or proteins (3).

Breast cancer, one of the common types of cancer for women, is the leading cause of death among women below the age of 50 years in western countries (4). Based on gene expression profiling, 4 different subtypes of breast cancer have been established, including luminal A, luminal B, HER2 and basal-like (BLBC). Understanding the relationship between the clinical symptoms and the molecular changes in breast cancer is of great importance for developing new diagnosis and treatment strategies for breast cancer patients. Recent studies have indicated that dysregulation of lncRNAs is closely associated with human diseases including cancers (5,6). For example, lncRNA focally amplified lncRNA on chromosome 1 (FAL1), whose copy number and expression are significantly correlated with poor prognosis of ovarian cancer patients. FAL1 directly interacts with the BMI1 and regulates its protein stability, and then modulates the transcription of several genes including CDKN1A (7). However, to date, only a few lncRNAs have been functionally identified in breast cancer, and the overall pathophysiological contributions of lncRNAs to breast cancer remain largely unknown.

In the present study, we identified a novel lncRNA termed lncFOXO1 through microarray screening, and demonstrated its suppressive role in breast cancer in vivo and in vitro. Mechanistically, lncFOXO1 suppressed the growth of breast cancer by increasing FOXO1 transcription. Moreover, we found that lncFOXO1 associated with BRCA-1-associated protein 1 (BAP1) and regulates its binding at FOXO1 promoter.

Materials and methods

Cell culture. Five breast cancer cell lines (MCF-7, BT-549, MB-231, MB-453 and MB-415) and a normal breast cell line (Hs-578Bst) were obtained from the Cell Bank of Chinese Academy of Sciences. Cells were cultured in Dulbecco's modified Eagle's medium (DMEM)/F12 (Gibco, Gaithersburg, MD, USA) supplemented with 10% fetal bovine serum (FBS; Gibco) and 1% penicillin-streptomycin (HyClone Laboratories, Inc., Logan, UT, USA). For establishing stable transfectants with lncFOXO1, cells were transfected with pCMV plasmid expressing full-length lncFOXO1.

Tissue samples. Fifty paired breast cancer and corresponding non-tumor breast tissues samples collected during breast cancer surgery were obtained from archived samples of the Tissue Bank at Cangzhou Central Hospital of Hebei Medical
University. All the patients gave informed consent for their tissues to be used for this research. Recommendations of the Declaration of Helsinki for biomedical research involving human subjects were also followed. Ethics approval for the study was obtained from the Ethics Committee of Cangzhou Central Hospital.

Cell viability detection. Cells/well (2x10³) were seeded in the 96-well plate and incubated for different time-points, respectively. Cell viability was measured with a Cell Counting kit-8 (CCK-8; Beyotime Institute of Biotechnology, Shanghai, China) following the manufacturer's instructions. Absorbance was measured at 450 nm using ELx800 reader (Bio-Tek Instruments, Inc., Winooski, VT, USA).

Colonies formation assay. Cells (2x10³) were seeded into a 6-well plate and cultured for 1 week at 37˚C. Cells were fixed with methanol and then stained with 0.005% crystal violet. Colonies were then counted.

Western blot analysis. The cells were lysed with RIPA buffer (Beyotime Institute of Biotechnology). Protein lysates were separated by SDS-PAGE and then transferred onto PVDF membranes. The membranes were blocked and incubated with anti-FOXO1 (Abcam, Cambridge, MA, USA), or BAP1 (Abcam) and GAPDH antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA) at 4˚C overnight. After being washed, the membranes were incubated with HRP-conjugated anti-IgG. Signal was detected by an ECL system (Amersham Pharmacia Biotech, Inc., Piscataway, NJ, USA).

Microarray analysis. Briefly, samples (6 paired breast cancer and corresponding non-tumor breast tissues) were used to synthesize double-stranded complementary DNA (cDNA), and double-stranded cDNA was labeled and hybridized to the 12x135K lncRNA Expression Microarray (Arraystar, Rockville, MD, USA). After hybridization and washing, processed slides were scanned with the Axon GenePix 4000B microarray scanner (Molecular Devices, Sunnyvale, CA, USA). Raw data were extracted as pair files using NimbleScan software (Roche NimbleGen, Inc., Madison, WI, USA). NimbleScan software implementation of RMA offers quantile normalization and background correction. Differentially expressed genes were identified through the random variance model. P-values were calculated using the paired t-test. The threshold set for upregulated and downregulated genes was a fold change ≥2.0 and a P<0.05. Hierarchical clustering was performed based on differentially expressed mRNAs and lncRNAs using Cluster TreeView software from Stanford University (Palo Alto, CA, USA).

Quantitative real-time PCR (qPCR). Total RNA was isolated using the RNeasy Mini kit (Qiagen) according to the manufacturer's instructions. Total RNA (1 µg) was reversely transcribed to cDNA by using EasyScript One-Step gDNA Removal and cDNA Synthesis (TransGen Biotech, Inc., Beijing, China). qPCR was performed on the StepOnePlus Detection System (Applied Biosystems, Foster City, CA, USA). Relative expression levels were calculated as ratios normalized against those of GAPDH. Comparative quantification was determined using the 2⁻ΔΔCt method. Primers can be found in Table I.

Isolation of cytoplasmic and nuclear RNA. Cytoplasmic and nuclear RNA was isolated and purified using the Cytoplasmic and Nuclear RNA Purification kit (Norgen, Inc., Belmont, CA, USA) according to its manual.

5'-3' Rapid amplification of cDNA ends (RACE). We used the 5'-RACE and 3'-RACE analyses to determine the transcriptional initiation and termination sites of IncRNA-ATB and IncRNA-508851 using a SMARTer™ RACE cDNA Amplification kit (Clontech Laboratories, Inc., Palo Alto, CA, USA) according to the manufacturer's instructions.

Cell cycle assay. The cell cycle was analyzed using an In Situ Cell Proliferation kit FLUOS (Roche Diagnostics) according to the manufacturer's instructions. The cell cycle distribution was analyzed by flow cytometry. The data were analyzed by FlowJo software (Tree Star, Inc., Ashland, OR, USA).

Apoptosis assay. Cells were stained with fluorescein isothiocyanate-conjugated Annexin V and 7-AAD (Apoptosis detection kit; Nanjing KeyGen Biotech, Co., Ltd., Nanjing, China) according to the manufacturer's instruction. Cells were analyzed with flow cytometer, and the data were studied using FlowJo software (Tree Star).

Chromatin immunoprecipitation (ChIP). ChIP assay was performed using the HiSense EZ-Magna ChiP™ Chromatin Immunoprecipitation kit (Millipore, Billerica, CA, USA), according to the manual. Briefly, crosslinked chromatin was sonicated into 200 to 1000 bp fragments. The chromatin was immunoprecipitated using anti-BAP1 (Abcam) and anti-ubH2AK119 (Abcam). Normal rabbit immunoglobulin G (IgG) was used as a negative control. Quantitative PCR was conducted using SYBR-Green Mix (Takara Bio, Shiga, Japan). Primer sequences are listed in Table I.

RNA pull-down and mass spectrometry assay. RNA pull-down was performed as previously described (7). In vitro biotin-labeled RNAs (IncFOXO1 and its antisense RNA) were transcribed with the biotin RNA labeling mix (Roche) and T7

<table>
<thead>
<tr>
<th>Gene symbol</th>
<th>Sequences</th>
</tr>
</thead>
<tbody>
<tr>
<td>GAPDH</td>
<td>Forward: GATTCCACCCATGGCAAAATTC\n</td>
</tr>
<tr>
<td>FOXO1</td>
<td>Forward: GATCTACGATGGATGTCGAG\n</td>
</tr>
<tr>
<td>IncFOXO1</td>
<td>Forward: CGATGGTGCTGGAGTAGTGTG\n</td>
</tr>
<tr>
<td>ChIP-FOXO1</td>
<td>Forward: GCCGCAGATCCCGTAAGT\n</td>
</tr>
</tbody>
</table>
RNA polymerase (Roche) treated with RNase-free DNase I (Promega, Madison, WI, USA) and purified with RNeasy Mini kit (Qiagen). Biotinylated RNA was incubated with nuclear extracts of breast cancer cells and pull-down proteins were run on SDS-PAGE gels. Mass spectrometry followed.

**RNA-FISH.** Fluorescence-conjugated lncFOXO1 probes were used for RNA-FISH. RNA-FISH was performed by using RNA-FISH kit (Wuhan Boster Biological Technology, Ltd., Wuhan, China) according to the standard protocol. Cells were observed with a FV1000 confocal laser microscope (Olympus).

**Statistical analysis.** All the statistical analyses were performed using SPSS software. For comparisons, two-tailed Student's t-tests were performed. Survival curve was evaluated using the Kaplan-Meier method and the differences were assessed using the log-rank test.

**Results**

**Downregulation of lncFOXO1 expression in human breast cancer tissues.** Firstly, the Agilent G3 Human GE Microarray (8x60 K) was used to analyze IncRNA expression profiles in 6 paired breast cancer tissues and corresponding non-tumor tissues. Fold change >2.0 and P<0.05 between tumor tissues and corresponding non-tumor tissues were set as the criteria in filtering differently expressed IncRNAs. Results of unsupervised hierarchical clustering analysis on the significantly dysregulated IncRNAs are shown in Fig. 1A.

A previous study showed that IncRNAs act in cis to regulate expression of neighboring genes or in trans (8). Therefore, we concentrated on intergenic IncRNAs which were aberrantly expressed in breast cancer tissues and located in the nearby coding genes related to breast development. Among these highly expressed intergenic IncRNAs, we focused on an uncharacterized IncRNA, termed lncFOXO1 (gene symbol RP11-172E9.2). lncFOXO1 is one of the most decreased IncRNAs in breast cancer, residing on chromosome 13 upstream of FOXO1 gene. We next examined a cohort of 50 paired breast cancer and corresponding non-tumor breast tissues. We observed that lncFOXO1 was significantly decreased in breast cancer tissues (Fig. 1B). Furthermore, we found that patients with high lncFOXO1 expression in breast cancer had a better prognosis than those with low lncFOXO1 expression (Fig. 1C). Taken together, these data suggest an important role for lncFOXO1 in breast cancer.

**Characterization of lncFOXO1.** A total length of 683 nt of lncFOXO1 transcript was determined by a RACE assay (Fig. 2A). Next, we determined the cellular location of lncFOXO1. RNA-FISH and cellular fractionation assays showed that lncFOXO1 was mainly localized in the nuclei of breast cancer cells (Fig. 2B and C).

**Overexpression of lncFOXO1 inhibits cell proliferation, colony formation, and induces G0/G1 cell cycle arrest and apoptosis in breast cancer cells.** Next, we determined the biological function of lncFOXO1 in breast cancer cells. Firstly, an analysis of lncFOXO1 expression was carried out among 5 different breast cancer cell lines (MCF-7, BT-549, MB-231, MB-453 and MB-415) and a normal breast cell line (Hs-578Bst). We noted that lncFOXO1 was obviously down-
Figure 2. Characterization of lncFOXO1. (A) A representative image of PCR products from the 5'-RACE and 3'-RACE procedure. The major PCR product is marked by an arrow. (B) lncFOXO1 intracellular localization was visualized in BT-549 cells by RNA-FISH assays. (C) Fractionation of BT-549 cells followed by qPCR.

Figure 3. Overexpression of lncFOXO1 inhibits cell proliferation, colony formation, and induces G0/G1 cell cycle arrest and apoptosis in breast cancer cells. (A) lncFOXO1 expression was determined by qPCR in normal breast cells (Hs-578Bst) and 5 different breast cancer cell lines. (B) The relative expression of lncFOXO1 in control and lncFOXO1 overexpressed cells. (C) The cell proliferation was detected by CCK-8 assay in control and lncFOXO1 overexpressed cells. (D) The clone formation was detected in control and lncFOXO1 overexpressed cells. (E) The cell cycle distribution was determined in control and lncFOXO1 overexpressed cells by flow cytometry. (F) Apoptosis was determined in control and lncFOXO1 overexpressed cells by flow cytometry. (G) Effects of lncFOXO1 overexpression on tumor growth in vivo. Tumor growth curves measured after injection of BT-549 cells expressing control and lncFOXO1. Data are shown as mean ± SD. *P<0.05.
regulated in 5 breast cancer cell lines compared to that of Hs-578Bst cells, especially in BT-549 and MB-231 cell lines (Fig. 3A). Thus, BT-549 and MB-231 cell lines were selected as breast cancer cells in the following studies.

Then, we constructed stable cells with lncFOXO1 overexpression (Fig. 3B). To detect the effects of lncFOXO1 overexpression on cell proliferation, CCK-8 assay was performed. Compared with empty vector transfected cells, a significant decrease of cell viability was observed in BT-549 and MB-231 cells (Fig. 3C). To further confirm the inhibitory effect of lncFOXO1 overexpression on the proliferation of breast cancer cells, colony formation assay was performed. As shown in Fig. 3D, the colony numbers of BT-549 and MB-231 cells with lncFOXO1 overexpression were significantly lower than that of control cells, indicating that lncFOXO1 inhibited in vitro proliferation of breast cancer cells.

We further analyzed the cell cycle distribution and apoptosis using flow cytometry in BT-549 and MB-231 cells with lncFOXO1 overexpression. Compared with the control cells, lncFOXO1-overexpressed cells showed cell cycle arrest in G0/G1 phase (Fig. 3E). In addition, lncFOXO1 overexpression significantly promoted cell apoptosis in both BT-549 and MB-231 cells (Fig. 3F). The results showed that lncFOXO1 induces G0/G1 cell cycle arrest and apoptosis in breast cancer cells.

To assess the influence of lncFOXO1 overexpression on the in vivo growth of breast cancer cells, we applied a xenograft model in which the control and lncFOXO1 overexpressed BT-549 cells were subcutaneously injected into the flank of athymic nude mice. Our results showed that the growth of tumors from lncFOXO1-overexpression xenografts was significantly inhibited, compared with that of tumors formed from control xenografts (Fig. 3G). Taken together, these results suggest that lncFOXO1 inhibited both in vitro and in vivo growth of breast cancer cells.

lncFOXO1 triggers FOXO1 expression. Next, we explored the molecular mechanisms by which lncFOXO1 suppressed the proliferation of breast cancer cells. Firstly, we detected the neighboring gene FOXO1 expression in control and lncFOXO1-overexpressed cells. Notably, lncFOXO1 overexpression significantly increased both mRNA and protein level of FOXO1 expression (Fig. 4A). We detected the expression levels of lncFOXO1 and FOXO1 in breast cancer samples by qPCR. We noticed that lncFOXO1 expression was positively correlated with the expression of FOXO1 ($r^2=0.6988$, $P<0.0001$; Fig. 4B). To determine whether lncFOXO1 functions upstream of FOXO1 in the regulation of cell proliferation in breast cancer, we silenced FOXO1 expression in lncFOXO1-overexpressed breast cancer cell lines (Fig. 4C). Notably, silence...
of FOXO1 abolished the growth suppression induced by lncFOXO1 overexpression (Fig. 4D and E). These data demonstrated that lncFOXO1 suppressed cell proliferation of breast cancer cells through upregulation of FOXO1.

**BAP1 is recruited by lncFOXO1.** Finally, we explored the regulatory mechanism of FOXO1 expression mediated by lncFOXO1. lncRNAs are considered to exert their functions through RNA-interacting proteins that regulate gene expression by various mechanisms. Therefore, we performed an RNA pull-down assay with biotin-labeled lncFOXO1 and followed by mass spectrum to search for potential lncFOXO1-associated proteins. The deubiquitinating enzyme BRCA-1-associated protein 1 (BAP1) were identified to potentially interact with lncFOXO1 in breast cancer cells (Fig. 5A). The interaction of lncFOXO1 with BAP1 was further validated by RNA immunoprecipitation (RIP) (Fig. 5B). We next constructed a series of lncFOXO1 truncations to map its binding fragment with BAP1. We found that the 3'-end fragment of lncFOXO1 (468 to 683 nt) was essential to bind BAP1 (Fig. 5C).

lncFOXO1 overexpression did not influence protein level of BAP1 (Fig. 5D), suggesting that lncFOXO1 was not involved in the post-translational regulation of the BAP1. Given that the BAP1 regulates gene transcription via binding to promoter region and deubiquitinate mono-ubiquitinated H2A at K119 (ubH2AK119), we then detected whether lncFOXO1 influenced BAP1 occupancy and the level of ubH2AK119 across FOXO1 promoter region by performing ChIP assays. We found that lncFOXO1 overexpression increased the binding of BAP1 to FOXO1 promoter (Fig. 5E), and decreased the level of ubH2AK119 across FOXO1 promoter region (Fig. 5F). In addition, BAP1 deletion significantly abolished the upregulation of FOXO1 induced by lncFOXO1 overexpression. Data are shown as mean ± SD, *P<0.05. **

Figure 5. lncFOXO1 recruits the BAP1. (A) Biotin-RNA pull-downs were performed with nuclear extracts of oncosphere cells using full-length lncFOXO1 transcript (sense) and antisense. This was followed by mass spectrometry. (B) The interaction of lncFOXO1 with BAP1 was verified by an RNA immunoprecipitation (RIP) assay. (C) Mapping analysis of BAP1-binding domains of lncFOXO1. Shown are the following: schematic diagram of lncFOXO1 full-length and truncated fragments (top panel) and western blot analysis of BAP1 in RNA pull-down samples by different lncFOXO1 fragments (bottom panel). (D) The protein level of BAP1 was analyzed by western blot analysis in control and lncFOXO1 overexpressed cells. (E) The binding level of BAP1 at FOXO1 promoter region was determined by ChIP assay and followed by qPCR in control and lncFOXO1 overexpressed cells. (E) The ubH2AK119 level of FOXO1 promoter region was determined by ChIP assay and followed by qPCR in control and lncFOXO1 overexpressed cells. (G) BAP1 deletion significantly abolished the upregulation of FOXO1 induced by lncFOXO1 overexpression. Data are shown as mean ± SD, *P<0.05.
of FOXO1 induced by IncFOXO1 overexpression (Fig. 5G). Taken together, our data demonstrated that IncFOXO1 triggers FOXO1 expression through recruitment of BAP1, leading to suppression of the proliferation of breast cancer cells.

Discussion

In the present study, we revealed the critical roles of IncFOXO1 in breast cancer proliferative phenotype and clinical prognosis, based on the following observations: i) IncFOXO1 is significantly decreased in breast cancer tissues and cell lines; ii) downregulation of IncFOXO1 expression associates with poorer overall survival; iii) overexpression of IncFOXO1 inhibits the in vitro and in vivo growth of breast cancer cells; iv) IncFOXO1 activates FOXO1 expression through recruiting BAP1 and decreasing the ubH2AK119 at FOXO1 promoter.

Increasing evidence reports that numerous lncRNAs are frequently aberrantly expressed in different kinds of cancers, exhibiting regulated gene expression variously (9,10). These differential expression lncRNAs are closely associated to tumorigenesis, metastasis, prognosis or diagnosis, serving as oncogenes or/tumor suppressor genes (9). However, there are few studies on tumor suppressive IncRNA in breast cancer. In the present study, we identified a novel lncRNA that exerts tumor suppressive activity in breast cancer. We found that IncFOXO1 inhibits the growth of breast cancer cells both in vitro and in vivo. IncFOXO1 may be a potential target for therapy of breast cancer.

Notably, accumulating evidence shows that lncRNAs modulate gene expression as epigenetic modifiers. Here, for the first time, we found that IncFOXO1 activates FOXO1 expression through recruitment of BAP1. BAP1 is a critical tumor suppressor, and loss of BAP1 expression leads to a variety of cancers including pleural mesothelioma, renal cell carcinoma and bladder tumors. Decrease of BAP1 expression is significantly associated with high tumor aggressiveness and poor prognosis (11-13). BAP1 regulates the expression of target genes through association with transcription-related proteins such as ASXL1 and ASXL2. BAP1 deubiquitimates ubH2AK119 of target genes to activate their transcription (14). In the present study, we found that FOXO1 also is a direct target gene of BAP1. Overexpression of IncFOXO1 increased the binding of BAP1 at FOXO1 promoter, and decreased the level of ubH2AK119 across FOXO1 promoter. Overall, we proposed a novel model in which IncFOXO1 associates with chromatin-modifying factor BAP1 to regulate FOXO1 expression in breast cancer.

Previous studies reported that lncRNAs can act in cis to regulate expression of neighboring genes. For example, IncTCF7 recruits the SWI/SNF complex to the promoter of TCF7 to regulate its expression, leading to activation of Wnt signaling (15). FOXO1 is considered as a tumor suppressor that inhibits cell proliferation and induce apoptosis. FOXO1 alterations have been described in a number of human cancers, such as rhabdomyosarcoma, leukemia and lymphoma (16-18). In addition, FOXO1 proteins are inactivated by major oncogenic signals such as the phosphatidylinositol-3 kinase pathway (PI3K) and MAP kinases (MAPK) or microRNAs (19-21). In this study, we revealed a new regulatory mechanism of FOXO1 expression. We found that IncFOXO1 activates the expression of neighboring gene, FOXO1, through interaction with BAP1. Understanding the precise molecular mechanisms by which lncRNAs exert their function in breast cancer will be critical for exploring these potential new strategies for early diagnosis and therapy of breast cancer.

In conclusion, IncFOXO1 suppresses the growth of breast cancer cells by recruiting BAP1 to the FOXO1 promoter. Our findings reveal that lncRNAs may represent an additional layer of regulation of the tumor suppressor.

Acknowledgements

The present study was supported by grants from the Cangzhou Key Technology Support Program (no. 131302120).

References


